Vaxcyte

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Carlos, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxcyte reports robust Q4 performance and eyes vaccine market growth

Vaxcyte's Q4 performance highlighted strong financials, promising pipeline programs, and strategic market positioning.
The company faces challenges in pediatric efficacy translation, differentiation, and operational scalability.
Opportunities lie in expanding manufacturing, leveraging unique vaccine approaches, and addressing critical medical needs.

Vaxcyte excels in 2023 with strong PCV progress and financial growth

Vaxcyte's strong performance in 2023, with progress in key PCV candidates and financial strength, positions them well in the competitive vaccine market. Challenges include uncertainties in the competitive landscape and adapting to different vaccination schedules globally. Opportunities lie in upcoming milestones, global commercialization, and meeting the demand for broadly protective vaccines.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025, Followed by Topline Data from Booster Dose by the End of 2025 -- -- VAX-24, a 24-Valent Pneumococcal Conjugate Vaccine (PCV), is Designed to Cover More Serotypes Than Any Infant Pneumococcal Vaccine On-Market or in U.S. Clinics Today --

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know

Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript

-- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult Program and End-of-Phase 2 Meeting; VAX-24 is Phase 3-Ready in Adults --

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Vaxcyte (PCVX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Vaxcyte (PCVX) Might Surprise This Earnings Season

Apellis Pharma

Constellation Energy Corp

HEICO

Inter Parfums

We have narrowed our search to five stocks that are poised to beat on earnings this week. These are: HEi, CEG, IPAR, APLS, PCVX.

5 Stocks to Buy That Are Poised to Beat on Earnings This Week

SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2023 after market close on February 27, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,695,312 shares of common stock at a public offering price of $64.00 per share and pre-funded warrants to purchase 781,250 shares of common stock at a public offering price of $63.999 per underlying share. This includes the exercise in full by the underwriters of their option to purchase up to 1,757,812 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $862.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN CARLOS, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on Thursday, February 8, 2024 at 10:00 a.m. ET / 7:00 a.m. PT.

Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

SAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $750.0 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,757,812 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.

Vaxcyte Announces Pricing of $750 Million Public Offering

-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed to Provide Coverage for Approximately 95% of IPD Circulating in the U.S. Adult Population --

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

-- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Whitney Jones as Chief People Officer. Ms. Jones will lead Vaxcyte's human resources strategy and operations, including people and culture, talent acquisition and management, learning and development, total rewards and employee engagement.

Vaxcyte Appoints Whitney Jones as Chief People Officer

-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in  Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following Successful End-of-Phase 2 Meeting with FDA, Company Planning for Initiation of VAX-24 Adult Phase 3 Pivotal, Non-Inferiority Study in Second Half of 2024; Topline Data Expected in Second Half of 2025 --

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

--   In the Study,   VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 ® (PCV20) at all Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met or Exceeded Regulatory Immunogenicity Standards --

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

SAN CARLOS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Jacks Lee to its Board of Directors.

Vaxcyte Appoints Jacks Lee to Board of Directors

-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company's Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement Further Strengthens Vaxcyte's Long-Term, Global Commercial Manufacturing Strategy as Lead PCV Candidate, VAX-24, Advances into Phase 3 --

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

-- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline Safety, Tolerability and Immunogenicity Data Expected in Second Half of 2024 --

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

-- Completed Successful End-of-Phase 2 Meeting with FDA for VAX-24; Topline Phase 3 Data in Adults Expected in 2025 --    -- Received FDA Clearance of VAX-31 Adult IND Application; Phase 1/2 Study Initiation Expected This Quarter and Topline Data Expected in the Second Half of 2024 --

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences:

Vaxcyte to Present at Upcoming Investor Conferences

-- Company Expects to Initiate VAX-31 Phase 1/2 Study in Healthy Adults This Quarter-- -- Topline Safety, Tolerability and Immunogenicity Results from VAX-31 Phase 1/2 Study Expected in the Second Half of 2024 --

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. is making substantial progress with its vaccine candidate VAX-24 for the prevention of invasive pneumococcal disease as evidenced by trial data. Obtained positive immunogenicity data from its phase 2 study in adults for prevention of IPD and expects to meet with the FDA in Q4 2023 for phase 3. Vaxcyte faces competition from other pneumococcal vaccine companies, but its 24-valent PCV could provide superior protection compared to existing options; Plus it has potential to advance a 31-valent PCV.

Vaxcyte: End Of Phase 2 Meeting FDA Q4 Of 2023 To Get Ball Rolling

-- New Agreement to Establish Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, VAX-24 and VAX-31, in Adult and Pediatric Populations -- -- Expanded Collaboration Builds on Vaxcyte's Current Strategy to Conduct Initial Commercial Launch of VAX-24 in Adults from Existing Lonza Facilities in Visp (CH) --

Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)

SAN CARLOS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26, 2023 at 11:40 a.m. ET / 8:40 a.m. PT.

Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

Vaxcyte, Inc. is a clinical-stage vaccine company developing high-fidelity vaccines for bacterial diseases. The company's Q2 2023 earnings report shows significant growth in cash and investments, indicating a solid liquidity position. Positive Phase 2 data for Vaxcyte's VAX-24 vaccine and a promising pipeline make it a recommended speculative "Buy" for investors.

Strong Financials And Pipeline Position Vaxcyte For Success

-- Advanced Ongoing VAX-24 Phase 2 Infant Study to Second Stage, Dosing First New Participants in July 2023; Topline Data from Primary Immunization Series Expected by 2025 -- -- Completed Phase 2 VAX-24 Adult Program for the Prevention of Invasive Pneumococcal Disease (IPD); Topline Phase 3 Data Expected in 2025 --

News for Vaxcyte Stock (PCVX)